In summary, the STMN1-immunostaining-contained new method is easier and more accurate for the diagnosis of MVI and the estimation of HCC prognosis, and therefore has an important clinical application value in diagnosing the risk level of MVI in patients with early HCC. The gene discussed is STMN1; the disease is hepatocellular carcinoma.